share_log

ARS: Annual Report to Security Holders

ARS: Annual Report to Security Holders

ARS：年度报告
美股SEC公告 ·  05/09 16:34
Moomoo AI 已提取核心信息
SeaStar Medical Holding Corporation, a medical technology company, reported a net loss of $26.2 million for the fiscal year ended December 31, 2023, compared to a net loss of $12.2 million for the previous year. The increased net loss was primarily due to higher research and development expenses, general and administrative costs, and non-cash, non-operating losses related to changes in the fair value of financial instruments. The company has not generated significant revenue from product sales and continues to rely on equity and debt financing to fund operations. SeaStar Medical's financial statements for 2023 have been restated to correct material misstatements, and the company has identified material weaknesses in its internal controls over financial reporting. As of December 31, 2023, SeaStar Medical had cash of $0.2 million and an accumulated deficit of $114.7 million. The company's ability to continue as a going concern is uncertain, and it will need to raise additional capital to fund its operations, including clinical trial expenses and regulatory approval efforts.
SeaStar Medical Holding Corporation, a medical technology company, reported a net loss of $26.2 million for the fiscal year ended December 31, 2023, compared to a net loss of $12.2 million for the previous year. The increased net loss was primarily due to higher research and development expenses, general and administrative costs, and non-cash, non-operating losses related to changes in the fair value of financial instruments. The company has not generated significant revenue from product sales and continues to rely on equity and debt financing to fund operations. SeaStar Medical's financial statements for 2023 have been restated to correct material misstatements, and the company has identified material weaknesses in its internal controls over financial reporting. As of December 31, 2023, SeaStar Medical had cash of $0.2 million and an accumulated deficit of $114.7 million. The company's ability to continue as a going concern is uncertain, and it will need to raise additional capital to fund its operations, including clinical trial expenses and regulatory approval efforts.
医疗技术公司SeaStar Medical Holding Corporation报告称，截至2023年12月31日的财年净亏损为2620万美元，而上一年的净亏损为1,220万美元。净亏损增加的主要原因是研发费用、一般和管理成本增加，以及与金融工具公允价值变动相关的非现金和非营业亏损。该公司尚未从产品销售中获得可观的收入，并继续依靠股权和债务融资为运营提供资金。SeaStar Medical重报了2023年的财务报表，以纠正重大错误陈述，该公司已发现其财务报告内部控制存在重大缺陷。截至2023年12月31日，海星医疗的现金为20万美元，累计赤字为1.147亿美元。该公司继续经营的能力尚不确定，它将需要筹集额外资金来为其运营提供资金，包括临床试验费用和监管部门的批准工作。
医疗技术公司SeaStar Medical Holding Corporation报告称，截至2023年12月31日的财年净亏损为2620万美元，而上一年的净亏损为1,220万美元。净亏损增加的主要原因是研发费用、一般和管理成本增加，以及与金融工具公允价值变动相关的非现金和非营业亏损。该公司尚未从产品销售中获得可观的收入，并继续依靠股权和债务融资为运营提供资金。SeaStar Medical重报了2023年的财务报表，以纠正重大错误陈述，该公司已发现其财务报告内部控制存在重大缺陷。截至2023年12月31日，海星医疗的现金为20万美元，累计赤字为1.147亿美元。该公司继续经营的能力尚不确定，它将需要筹集额外资金来为其运营提供资金，包括临床试验费用和监管部门的批准工作。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息